Editorially independent content, supported with advertising
12.12.24
What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitamins.
Editorially Independent content supported by Astellas.
12.12.24
GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?John Kitchens, MD; Saradha Chexal, MD; and Geeta Lalwani, MD
Editorially Independent content supported by Astellas.
10.28.24
GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?John Kitchens, MD, Miguel Busquets, MD, and Esther Kim, MD
Editorially Independent content supported by Astellas.
05.10.24
GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment StrategiesDavid RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD
Editorially Independent content supported by Astellas.
05.10.24
GA Options in Clinical Therapy, Part 2: Real-World Cases in GADavid RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD
Editorially Independent content supported by Astellas.